Q2 2024 Earnings Estimate for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Issued By William Blair

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) – Equities researchers at William Blair upped their Q2 2024 earnings per share (EPS) estimates for shares of Fusion Pharmaceuticals in a research report issued on Tuesday, May 7th. William Blair analyst A. Hsieh now anticipates that the company will earn ($0.39) per share for the quarter, up from their prior forecast of ($0.42). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Fusion Pharmaceuticals’ current full-year earnings is ($1.46) per share. William Blair also issued estimates for Fusion Pharmaceuticals’ Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($1.58) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.65) EPS.

FUSN has been the topic of several other reports. Leerink Partnrs downgraded Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th. Truist Financial restated a “hold” rating and set a $21.00 price target (up previously from $11.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. B. Riley lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the company from $13.00 to $23.00 in a research report on Wednesday, March 20th. Jonestrading reissued a “hold” rating on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $21.00 price target (up previously from $10.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Thirteen investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.25.

Fusion Pharmaceuticals Price Performance

NASDAQ FUSN opened at $21.38 on Thursday. The firm’s fifty day simple moving average is $18.46 and its two-hundred day simple moving average is $11.47. The firm has a market capitalization of $1.81 billion, a P/E ratio of -14.54 and a beta of -0.69. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16. Fusion Pharmaceuticals has a 12-month low of $2.31 and a 12-month high of $21.58.

Fusion Pharmaceuticals (NASDAQ:FUSN) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%.

Hedge Funds Weigh In On Fusion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Yarbrough Capital LLC purchased a new stake in shares of Fusion Pharmaceuticals in the fourth quarter valued at approximately $739,000. HealthInvest Partners AB acquired a new position in shares of Fusion Pharmaceuticals during the 4th quarter valued at about $1,201,000. Jennison Associates LLC acquired a new stake in Fusion Pharmaceuticals during the fourth quarter worth about $2,893,000. Federated Hermes Inc. raised its stake in Fusion Pharmaceuticals by 1.9% during the fourth quarter. Federated Hermes Inc. now owns 10,886,153 shares of the company’s stock worth $104,616,000 after purchasing an additional 202,364 shares during the period. Finally, Forefront Analytics LLC boosted its holdings in Fusion Pharmaceuticals by 67.8% in the 3rd quarter. Forefront Analytics LLC now owns 33,685 shares of the company’s stock valued at $88,000 after purchasing an additional 13,610 shares during the last quarter. Institutional investors and hedge funds own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.